Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Can Fite Biopharma's enterprise value is $-1.52 Mil.
Can Fite Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-9.93 Mil. Therefore, Can Fite Biopharma's EV-to-EBITDA for today is 0.15.
The historical rank and industry rank for Can Fite Biopharma's EV-to-EBITDA or its related term are showing as below:
CANF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.36 Med: -0.48 Max: 0.59
Current: 0.15
During the past 13 years, the highest EV-to-EBITDA of Can Fite Biopharma was 0.59. The lowest was -6.36. And the median was -0.48.
CANF's EV-to-EBITDA is ranked better than 94.43% of 395
companies
in the Biotechnology industry
Industry Median: 13
vs CANF: 0.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Can Fite Biopharma (AMEX:CANF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Can Fite Biopharma's PE Ratio (TTM) for today is calculated as:
Can Fite Biopharma's share price for today is $3.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.782.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Can Fite Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's EV-to-EBITDA falls into.
Can Fite Biopharma's current Enterprise Value is $-1.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-9.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a EV-to-EBITDA of 0.15 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Can Fite Biopharma. According to the industry distribution chart, Can Fite Biopharma ranks #22 out of 395 companies in the Biotechnology industry, placing it in the top 5.6%.
Is Can Fite Biopharma's EV-to-EBITDA too high?
Can Fite Biopharma's current EV-to-EBITDA is 0.15. The Biotechnology industry median EV-to-EBITDA is 13.00. Can Fite Biopharma's value of 0.15 is 98.8% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #22 out of 395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #22 out of 395 companies for EV-to-EBITDA. This places Can Fite Biopharma in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.00. Can Fite Biopharma's value of 0.15 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.00, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current EV-to-EBITDA of 0.15 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Can Fite Biopharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current EV-to-EBITDA is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.24, compared to a current price of $3.22 — trading 48.4% below its estimated fair value. The current EV-to-EBITDA is 0.15 and 98.8% below the Biotechnology industry median of 13.00. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current EV-to-EBITDA is 0.15 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.22 is trading 48.4% below its estimated GF Value™ of $6.24.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
EV-to-EBITDA: 0.15
GF Value™: $6.24 vs. price of $3.22 (48.4% below fair value)
Industry Position: 98.8% below the Biotechnology median (#22 of 395)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
